| Literature DB >> 31009908 |
Zefeng Zhao1, Huanhuan Song2, Jing Xie1, Tian Liu1, Xue Zhao1, Xufei Chen1, Xirui He3, Shaoping Wu4, Yongmin Zhang5, Xiaohui Zheng6.
Abstract
TMCA (3,4,5-trimethoxycinnamic acid) ester and amide are privileged structural scaffolds in drug discovery which are widely distributed in natural products and consequently produced diverse therapeutically relevant pharmacological functions. Owing to the potential of TMCA ester and amide analogues as therapeutic agents, researches on chemical syntheses and modifications have been carried out to drug-like candidates with broad range of medicinal properties such as antitumor, antiviral, CNS (central nervous system) agents, antimicrobial, anti-inflammatory and hematologic agents for a long time. At the same time, SAR (structure-activity relationship) studies have draw greater attention among medicinal chemists, and many of the lead compounds were derived for various disease targets. However, there is an urgent need for the medicinal chemists to further exploit the precursor in developing chemical entities with promising bioactivity and druggability. This review concisely summarizes the synthesis and biological activity for TMCA ester and amide analogues. It also comprehensively reveals the relationship of significant biological activities along with SAR studies.Entities:
Keywords: 3,4,5-Trimethoxycinnamic acid; Antimicrobial agents; Antitumor agents; Antiviral agents; CNS agnets; Hematologic agents; SAR; TMCA derivatives; anti-inflammatory agents
Mesh:
Substances:
Year: 2019 PMID: 31009908 PMCID: PMC7115657 DOI: 10.1016/j.ejmech.2019.04.009
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514
Fig. 1Structure of 3,4,5-trimethoxycinnamic acid (TMCA).
Fig. 2Drug design strategy: based on Combination of Traditional Chinese Medicine Chemistry (CTCMC).
Fig. 3TMCA esters isolated from P. tenuifolia.
Inhibitory activity of soluble epoxide hydrolase and interaction for ester N2, N3, N4 and N5.
| Com. | Inhibitory activity | Interaction and Autodock score | |||
|---|---|---|---|---|---|
| 100 μM (%) | IC50 (μM) | Type | Hydrogen bonds (Å) | Binding energyb | |
| N2 | >100 | 9.1 | a | Tyr343(2.68), Gln384(2.79), Asn378(2.62), Met503(3.22) | −7.36 |
| N3 | >100 | 18.0 | a | Thr360(2.71), Gln384(3.06) | −6.79 |
| N4 | 97.4 | 27.2 | a | Gln384(2.91) | −8.27 |
| N5 | >100 | 6.4 | a | Asp335(3.30), Gln384(3.14) | −7.87 |
| AUDAc | 4.4 | ||||
a: competitive; b: kcal/mol; c: positive control.
Fig. 4TMCA esters isolated from other natural products.
Fig. 5Structure of piplartine.
Fig. 6Structure of synthetic TMCA ester derivatives as antitumor agents (S1-S10).
Fig. 7Structure of synthetic TMCA amide derivatives as antitumor agents (S11-S29).
Antitumor activity of S14in vitro.
| Amides | IC50 (μM) | ||||
|---|---|---|---|---|---|
| A549 | HCT116 | MDA-MB-231 | Hep3B | WI38 | |
| 3.94 | 9.85 | 6.07 | 16.69 | 19.60 | |
| Piplartine | 5.90 | 21.80 | 19.53 | 69.46 | 26.78 |
Cytotoxic activity (Concentration of drug causing 50% inhibition of cell growth) data of amides, S21, S22, S23 and CA-4 by SRB method.
| Com. | MCF7 | DU145 | HOP62 | HeLa | K562 | SK-OV-3 | Colo205 | MIA-PaCa-2 |
|---|---|---|---|---|---|---|---|---|
| 0.079 | 0.095 | 24.8 | 14.9 | 28.0 | 20.9 | 76.0 | 64.5 | |
| 0.056 | 0.060 | 0.090 | 7.5 | 0.094 | 0.099 | 0.099 | 29.9 | |
| 0.031 | 0.045 | 43.6 | 29.2 | 0.099 | 29.8 | 74.9 | 74.0 | |
| CA-4 | 0.033 | 0.046 | 0.15 | 0.008 | 0.031 | 31.6 | 0.025 | – |
Enzyme and cellular activities of amides S27, S28 and S29.
| Com. | IC50 MetAP2 (nM) | GI50 HUVEC (μM) | GI @ 5 μM HUVEC (%) |
|---|---|---|---|
| S27 | 177 | 0.67 | >98 |
| S28 | 755 | – | 93 |
| S29 | 67 | 0.85 | >98 |
Fig. 8Structure of synthetic TMCA derivatives as antivival agents (S30-S35).
Anti-HBV activity and cytotoxicity of esters S30, S31, S32 and S33.
| Com. | CC50 (μM) | HBsAg | HBeAg | DNA replication | |||
|---|---|---|---|---|---|---|---|
| IC50 (μM) | SI | IC50 (μM) | SI | IC50 (μM) | SI | ||
| S30 | 506.99 | 107.19 | 4.73 | 74.80 | 6.78 | 141.46 | 3.58 |
| S31 | >1821.75 | 5.52 | >330.0 | 5.52 | >330.0 | 2.44 | >746.6 |
| S32 | 211 | 753 | – | 518 | 1.6 | 53.1 | 3.0 |
| S33 | >2423.5 | 285.7 | >8.5 | >2423.5 | – | 114.9 | >21.1 |
Fig. 9Structure of synthetic TMCA ester derivatives as CNS agents (S36-S39).
Fig. 10Structure of synthetic TMCA amide derivatives as CNS agents (S40-S48).
Serotonin (5-HT) receptor and transporter binding afnities of amides S40 and S41.
| Compound | Receptor binding affinity (IC50, μM) | |||||
|---|---|---|---|---|---|---|
| 5-HT1A | 5-HT2A | 5-HT2C | 5-HT6 | 5-HT7 | 5-HT transporter | |
| S40 | 1.2 | >10 | 8.8 | >10 | >10 | >10 |
| S41 | 2.1 | 6.8 | 4.5 | 5.0 | 5.6 | 6.7 |
| TMCA | 7.6 | >10 | 2.5 | >10 | >10 | >10 |
Fig. 11Structure of synthetic TMCA amide derivatives as antimicrobial agents (S49-S54).
Fig. 12Structure of synthetic TMCA amide derivatives as antimicrobial agents (S55-S59).
Antimicrobial activity of amides S55 and S56.
| Com. | Fungus | Bacteria | CC50 | ||||
|---|---|---|---|---|---|---|---|
| C. albicans ATCC 10231 | C. krusei ATCC 6258 | C. glabrata ATCC 90030 | C. parapsilosis ATCC 22019 | BHK-21 | |||
| 375.79 (0.61) | 375.79 (0.61) | - | 375.79 (0.61) | 375.79 (0.61) | 85.20 (2.71) | 231.71 | |
| – | 97.67 (1.89) | 48.83 (3.79) | – | – | – | 185,55 | |
| Piplartine | 94.60 (0.42) | – | 189.20 (0.21) | 189.20 (0.21) | 94.60 (0.42) | 315.33 (0.12) | 40.14 |
IC50 (SI).
Inactive at highest evaluated concentration.
Antimicrobial activity of amides S58 and S59.
| Com. | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | 0.5 | 1 | 4 | 4 | 32 | 2 | 16 | 64 | |
| 0.5 | 0.06 | 0.25 | 2 | 4 | 64 | 2 | 64 | 64 | |
| Azithromycin | 0.25 | 0.03 | 0.25 | 0.12 | 1 | 128 | 4 | 256 | ≥128 |
Fig. 13Structure of synthetic TMCA ester derivatives as anti-inflammatory agents (S60-S62).
Fig. 14Structure of synthetic TMCA amide derivatives as anti-inflammatory agents (S63-S67).
Fig. 15Structure of synthetic TMCA derivatives as hematologic agents (S68-S71).
Platelet anti-aggregatory activity of amides S68 and S69.
| Com. | Inhibition (%) | ||
|---|---|---|---|
| PAF receptor binding to rabbit platelet | ADP induced platelet aggregation | PAF induced platelet aggregation | |
| Dose | 20 μg/mL | 30 μg/mL | 50 μg/mL |
| 12 | 24.4 | 28.8 | |
| 19 | 29.1 | 39.3 | |
Platelet anti-aggregatory activity of amide S70.
| Com. | Conc. (μM) | Inhibition (%) | |||
|---|---|---|---|---|---|
| Collagen (2 μg/mL) | Arachidonic acid (100 μM) | PAF (10 nM) | Thrombin (100 μM) | ||
| 300 | 98.6 | 100 | 94.8 | – | |
| 150 | 97.2 | 100 | 56.9 | – | |
| Piplartine | 300 | 100 | 100 | 100 | 23.5 |
| 150 | 100 | 76.4 | 100 | – | |
| Acetylsalicylic acid | 300 | 5.8 | 100 | 0.3 | – |
| 150 | – | 75 | 0.3 | – | |
Fig. 16Structure of synthetic TMCA derivatives for other activities (S72-S74).